TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17881957

Group type: EXPERIMENTAL
Intervention: Baseline NIHSS scores
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: NIHSS items (level of consciousness, dysarthria, visual fields, worst motor score for the arms)
Number of subjects: 1000
Study: 14748814

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ro 48‐6791
Number of subjects: 18
Study: 11305828

Group type: EXPERIMENTAL
Intervention: Intrathecal 10 mg lidocaine plus 10 microg sufentanil (Group LS)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Intrathecal 20 microg sufentanil (Group S)
Number of subjects: 13
Study: 9383925

Group type: EXPERIMENTAL
Intervention: Massage therapy (15 minutes a day for 30 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxation therapy (control group)
Number of subjects: 0
Study: 8195735

Group type: EXPERIMENTAL
Intervention: 1% clotrimazole solution
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: 100% Melaleuca alternifolia (tea tree) oil
Number of subjects: 117
Study: 3661173

Group type: EXPERIMENTAL
Intervention: Early discharge (EG)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Late discharge (CG)
Number of subjects: 104
Study: 31929466

Group type: EXPERIMENTAL
Intervention: Feeling-focused ISTDP (FF-ISTDP)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Defense-focused ISTDP (DF-ISTDP)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study: 30078167

Group type: EXPERIMENTAL
Intervention: remifentanil + methadone (MET) (0.1 mg/kg IV over 15 min)
Number of subjects: 60

Group type: COMPARATOR
Intervention: remifentanil (REMI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: remifentanil + magnesium (MAG) (50 mg/kg bolus over 30 min followed by 10 mg/kg/h)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: remifentanil + methadone (MET)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: remifentanil + magnesium (MAG)
Number of subjects: 60
Study: 27528533

Group type: EXPERIMENTAL
Intervention: Three evidence-based programs with shared theories and intervention elements
Number of subjects: 0
Study: 26643501

Group type: EXPERIMENTAL
Intervention: CRUSADE score >40 with 24-month dual antiplatelet therapy
Number of subjects: 1946

Group type: EXPERIMENTAL
Intervention: CRUSADE score ≤40 with 24-month dual antiplatelet therapy
Number of subjects: 1946

Group type: COMPARATOR
Intervention: CRUSADE score >40 with 6-month dual antiplatelet therapy
Number of subjects: 1946

Group type: EXPERIMENTAL
Intervention: ACUITY score
Number of subjects: 1946

Group type: COMPARATOR
Intervention: HAS-BLED score
Number of subjects: 1946

Group type: EXPERIMENTAL
Intervention: CRUSADE score improvement
Number of subjects: 1946
Study: 23554277

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 103
Study: 20958276

Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Airway Scope
Number of subjects: 54

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 54
Study: 18831886

Group type: EXPERIMENTAL
Intervention: Risedronate (2.5 mg/day) and calcium (900 mg/day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Calcium (900 mg/day) alone
Number of subjects: 33
Study: 16487622

Group type: EXPERIMENTAL
Intervention: Immunosuppression with Basiliximab and cyclosporine with prednisone (St Group)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Immunosuppression with Basiliximab and cyclosporine without prednisone (NoSt Group)
Number of subjects: 198
Study: 12859610

Group type: EXPERIMENTAL
Intervention: Bi-directional bicycle pedal
Number of subjects: 19

Group type: COMPARATOR
Intervention: Traditional uni‐directional bicycle pedal (Control)
Number of subjects: 19
Study: 11268446

Group type: EXPERIMENTAL
Intervention: Oral HCFU, 300 mg daily for 52 weeks starting 2 weeks after surgery
Number of subjects: 316

Group type: COMPARATOR
Intervention: 5-FU intravenous injection, 333 mg/m2 body surface area/24 hours continuously for 72 hours starting on postoperative day 0 and 6
Number of subjects: 316
Study: 9069156

Group type: EXPERIMENTAL
Intervention: bb genotype
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: BB genotype
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bb genotype
Number of subjects: 90

Group type: COMPARATOR
Intervention: Osteoporosis patients
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Body weight
Number of subjects: 90
Study: 8256242

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (1 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Budesonide (1 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (matching)
Number of subjects: 9
Study: 3946550

Group type: EXPERIMENTAL
Intervention: Activity groups (drawing and making collages)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Discussion groups (describing positive life events)
Number of subjects: 22
Study: 29653535

Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care (CAU)
Number of subjects: 300
Study: 27219886

Group type: EXPERIMENTAL
Intervention: Synbiotic supplements containing 3 probiotic bacteria (Lactobacillus acidophilus 2×10^9, Lactobacillus casei 2×10^9, Bifidobacterium bifidum 2×10^9 CFU/g) plus 800 mg inulin
Number of subjects: 60
Study: 26133741

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus low‐molecular‐weight heparin calcium (n=44)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Conventional therapy (n=45)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus low‐molecular‐weight heparin calcium
Number of subjects: 89

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 89
Study: 23247052

Group type: EXPERIMENTAL
Intervention: Pharmacological weight loss treatment
Number of subjects: 119
Study: 21982660

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibition (ACE-I) with quinapril
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 78
Study: 18957616

Group type: EXPERIMENTAL
Intervention: Insulin with BQ-123 (type A endothelin receptor antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin with BQ-123
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin (higher dosing in obese subjects)
Number of subjects: 0
Study: 16565854

Group type: COMPARATOR
Intervention: Complete inflow occlusion (CIO)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Modified technique of hepatic vascular exclusion (MTHVE)
Number of subjects: 118

Group type: COMPARATOR
Intervention: CIO
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: MTHVE
Number of subjects: 118
Study: 12496951

Group type: EXPERIMENTAL
Intervention: Citalopram (10 mg, i.v.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 0
Study: 10815372

Group type: EXPERIMENTAL
Intervention: Balanced allocation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple randomization
Number of subjects: 0
Study: 8640056

Group type: EXPERIMENTAL
Intervention: Banked donor breast milk
Number of subjects: 54

Group type: COMPARATOR
Intervention: Preterm formula
Number of subjects: 54
Study: 1616160

Group type: EXPERIMENTAL
Intervention: Patient-controlled administration of alfentanil (lockout interval of 3 min)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Physician-controlled administration of alfentanil
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patient-controlled administration of alfentanil
Number of subjects: 80
Study: 6511230

Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride 0.01%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate 0.01%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride 0.02%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phosphate buffered saline (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate 0.01% (in humans)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride 0.01% (in humans)
Number of subjects: 0
Study: 31496668

Group type: EXPERIMENTAL
Intervention: Self-selected exercise (SSE) intensity session
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control session
Number of subjects: 20
Study: 29169572

Group type: EXPERIMENTAL
Intervention: Hysterectomy with opportunistic bilateral salpingectomy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard hysterectomy
Number of subjects: 104
Study: 26686380

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 9
Study: 24687921

Group type: EXPERIMENTAL
Intervention: onartuzumab plus erlotinib (O+E)
Number of subjects: 0

Group type: COMPARATOR
Intervention: erlotinib (Control)
Number of subjects: 0
Study: 23062116

Group type: EXPERIMENTAL
Intervention: Automated bolus advisor (BA)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group (MDI without BA)
Number of subjects: 226
Study: 20207925

Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) intervention with 2 automated calls over 10 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study: 17386191

Group type: EXPERIMENTAL
Intervention: CPAP 3 cm H20
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CPAP 6 cm H20
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CPAP 3 cm H20 plus PSV 8 cm H20
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CPAP 3 cm H20 plus PSV 12 cm H20
Number of subjects: 18
Study: 15808033

Group type: EXPERIMENTAL
Intervention: Cessation of quinine treatment
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Calf-stretching exercises
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 191
Study: 11991770

Group type: EXPERIMENTAL
Intervention: Isometric training of the non‐dominant forearm flexors at 80% of maximal voluntary contraction, 3 times per week for 8 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (CTL; N=7)
Number of subjects: 17
Study: 11210954

Group type: EXPERIMENTAL
Intervention: Thigh length graduated compression stockings
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Knee length graduated compression stockings
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group (no stockings)
Number of subjects: 5
Study: 15374134

Group type: EXPERIMENTAL
Intervention: 15 mg paroxetine daily for 42 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30 mg paroxetine daily for 42 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study: 8198851

Group type: EXPERIMENTAL
Intervention: School-based intervention programme involving nose blowing, deep breathing, coughing, and exercise performed daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 2822878

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme (ACE) inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other drugs (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimum effective dosage of ACE inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observation for at least 6 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supine rest, infusion of angiotensin II, atropine, saline
Number of subjects: 0
Study: 30365798

Group type: EXPERIMENTAL
Intervention: Ballroom dancing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no ballroom dancing)
Number of subjects: 60
Study: 27314763

Group type: EXPERIMENTAL
Intervention: Brief parent‐delivered treatment for child anxiety
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Treatment with strategies specifically targeting parental tolerance of their child's negative emotions
Number of subjects: 60
Study: 25714521

Group type: EXPERIMENTAL
Intervention: Clipping or coiling treatment (specifics on dosage and duration not available)
Number of subjects: 471

Group type: COMPARATOR
Intervention: Patients who did not receive a VPS at discharge
Number of subjects: 471
Study: 23225796

Group type: COMPARATOR
Intervention: Increased dose of clopidogrel (aspirin 100 mg + clopidogrel 150 mg daily)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Cilostazol (aspirin 100 mg + clopidogrel 75 mg + cilostazol 100 mg bid daily)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Crossover study after hyporesponsiveness
Number of subjects: 73
Study: 19906658

Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (200 mg bimonthly)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral iron sulphate (dosage not specified)
Number of subjects: 100
Study: 18221460

Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (0.25 mg twice daily for 6 weeks, then half dose for another 6 weeks)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nebulized fluticasone propionate (0.25 mg twice daily for 6 weeks, then half dose for another 6 weeks)
Number of subjects: 31
Study: 16011907

Group type: EXPERIMENTAL
Intervention: Mulligan's bent leg raise (BLR) technique, n=12
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo group, n=12
Number of subjects: 24
Study: 12798523

Group type: EXPERIMENTAL
Intervention: Doxycycline plus Azithromycin
Number of subjects: 597

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 597
Study: 11970744

Group type: EXPERIMENTAL
Intervention: Exemestane (EXE) 25 mg once daily (n=366)
Number of subjects: 769

Group type: COMPARATOR
Intervention: Megestrol acetate (MA) 40 mg four times daily (n=403)
Number of subjects: 769
Study: 8880945

Group type: EXPERIMENTAL
Intervention: lorazepam 0.038 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: diazepam 0.3 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 1521670

Group type: EXPERIMENTAL
Intervention: 300 mg buflomedil given orally twice daily for 90 days
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 31542243

Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg twice daily for a maximum of 52 weeks)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 69
Study: 29972120

Group type: EXPERIMENTAL
Intervention: Suspension exercise training in addition to routine rehabilitation training
Number of subjects: 97

Group type: COMPARATOR
Intervention: Routine rehabilitation training (Control)
Number of subjects: 97
Study: 26182441

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 4 mg/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dextrose placebo (PLA)
Number of subjects: 12
Study: 24284383

Group type: EXPERIMENTAL
Intervention: Endovascular stenting
Number of subjects: 15
Study: 22200399

Group type: EXPERIMENTAL
Intervention: Counseling by physical activity coaches
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group physician advice to exercise
Number of subjects: 226
Study: 20692031

Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (2 mL, three oral doses at 6, 10, and 14 weeks of age)
Number of subjects: 2036

Group type: COMPARATOR
Intervention: Placebo (three oral doses)
Number of subjects: 2036

Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine
Number of subjects: 2036

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2036
Study: 17557893

Group type: EXPERIMENTAL
Intervention: Newcomers criticizing their workplace (Experiment 1)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Newcomers criticizing their profession (Experiment 2)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Newcomers criticizing an Internet community (Experiment 3)
Number of subjects: 411
Study: 19902697

Group type: EXPERIMENTAL
Intervention: Educational video compact disc (VCD) and cataract information leaflets
Number of subjects: 463

Group type: COMPARATOR
Intervention: Cataract information leaflets
Number of subjects: 463
Study: 11979243

Group type: EXPERIMENTAL
Intervention: Midazolam (2 mg intravenously)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline solution (control group)
Number of subjects: 36
Study: 9469358

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 20 mg/m2
Number of subjects: 241

Group type: COMPARATOR
Intervention: Bleomycin and vincristine (BV) combination
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Number of subjects: 241
Study: 7637156

Group type: EXPERIMENTAL
Intervention: Amrinone infusion
Number of subjects: 26

Group type: COMPARATOR
Intervention: Normal saline infusion (Control)
Number of subjects: 26
Study: 2372037

Group type: EXPERIMENTAL
Intervention: Oral contraceptives containing 30 to 50 micrograms of ethinyl estradiol
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (healthy nonusers)
Number of subjects: 28
Study: 480949

Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol (DES) 5 mg orally t.i.d.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Diethylstilbestrol (DES) 5 mg orally t.i.d. + Chlorambucil (CB) 0.1‐‐0.2 mg/kg/day orally
Number of subjects: 34
Study: 29999394

Group type: EXPERIMENTAL
Intervention: Immediate mentalization-based Families and Carers Training and Support (5 sessions of 1.5-2 hours each)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Delayed intervention
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Immediate mentalization-based Families and Carers Training and Support
Number of subjects: 56
Study: 27705069

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Number of subjects: 0
Study: 25736355

Group type: EXPERIMENTAL
Intervention: CT-P13
Number of subjects: 0

Group type: COMPARATOR
Intervention: IFX
Number of subjects: 0
Study: 24158493

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Decongestant (xylometazoline hydrochloride, 0.05%)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: TLA with decongestant (lidocaine hydrochloride, 1% with xylometazoline hydrochloride, 0.05%)
Number of subjects: 69
Study: 21258848

Group type: EXPERIMENTAL
Intervention: Interactive website (www.wiagesprek.nl) with five interactive modules aimed at increasing knowledge, self‐awareness, expectations, self‐efficacy, and active participation.
Number of subjects: 242

Group type: COMPARATOR
Intervention: Control group directed to a 'sham' website with commonly available information only.
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Interactive website (www.wiagesprek.nl)
Number of subjects: 242
Study: 19636665

Group type: EXPERIMENTAL
Intervention: 15 degrees BOAD
Number of subjects: 179

Group type: COMPARATOR
Intervention: 5 degrees BOAD
Number of subjects: 179
Study: 17288611

Group type: EXPERIMENTAL
Intervention: Tetracaine 4% gel applied to the skin for 30 minutes
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo applied to the skin for 30 minutes
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Sucrose administration (24% sucrose)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Local skin reactions
Number of subjects: 142
Study: 14671041

Group type: EXPERIMENTAL
Intervention: On-line haemodiafiltration (HDF) using Helixone membrane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haemodialysis (HD) with Helixone membrane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: On-line HDF using standard polysulphone membrane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haemodialysis (HD) using polysulphone membrane
Number of subjects: 0
Study: 11330878

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 17
Study: 9401083

Group type: EXPERIMENTAL
Intervention: Intermediate-dose cytarabine (IDARA-C) plus idarubicin (IDA) and prednisone (PDN) during induction phase
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplant (BMT)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: All enrolled children
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Age < 10 years at initial diagnosis
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: First CR duration >= 12 months and WBC count at relapse < 20 x 10(9)/l
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Age >= 10 years at initial diagnosis and WBC count at relapse >= 20 x 10(9)/l
Number of subjects: 73
Study: 7525055

Group type: EXPERIMENTAL
Intervention: Carboplatin (CBDCA) at a maximum tolerated dose of 1000 mg/m2, administered at 14-day intervals, supported by peripheral blood progenitors and filgrastim.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Carboplatin (CBDCA) at various dose levels: Level I (500 mg/m2), Level II (800 mg/m2), Level III (1200 mg/m2), Level IIIa (1000 mg/m2), and Level IV (1000 mg/m2) plus cyclophosphamide (CPA) at 1500 mg/m2.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combination of CBDCA (1000 mg/m2) plus CPA (1500 mg/m2) in Level IV.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CPA) at a dose of 3.0 g/m2, supported by filgrastim.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: CBDCA dose intensities for each dose level: I (185 mg/m2), II (328 mg/m2), III (567 mg/m2), IIIa (465 mg/m2), Level IV (468 mg/m2).
Number of subjects: 31
Study: 3310924

Group type: EXPERIMENTAL
Intervention: 2.0 ppm formaldehyde exposure for 40 min
Number of subjects: 15

Group type: COMPARATOR
Intervention: Room air exposure
Number of subjects: 15
Study: 31155650

Group type: EXPERIMENTAL
Intervention: One-week amphotericin B plus flucytosine
Number of subjects: 236
Study: 28742756

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction (MBSR)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 342
Study: 25979307

Group type: EXPERIMENTAL
Intervention: Extended-release niacin 1500 mg/day with aspirin 325 mg/day
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg/day
Number of subjects: 99
Study: 24061336

Group type: EXPERIMENTAL
Intervention: Simulation-based learning with 2 additional hours of tuition using human patient simulators.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving identical blood pressure measurement education without additional simulation.
Number of subjects: 0
Study: 20538357

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) for women
Number of subjects: 802